Johnson & Johnson Biosense Webster
Irvine, Calif. (ots/PRNewswire) - - Regulatory approval for the first fully integrated PFA system with a CARTO-enabled simple and reproducible workflow. - Integrated with the world's leading CARTO™ 3D Cardiac Mapping System for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ...
Paris and Irvine, California (ots/PRNewswire) - Enevate's silicon-dominant Li-ion technology features extreme fast-charging capabilities with high energy density and improved safety Alliance Ventures, the strategic venture capital arm of Renault-Nissan-Mitsubishi, has announced today that it has invested in the latest round of funding in Enevate Corporation, an ...
Axonics Modulation Technologies, Inc.
Irvine, California (ots/PRNewswire) - Post-market Clinical Study Evaluates Axonics Miniaturized, Rechargeable System for Overactive Bladder Patients Axonics Modulation Technologies, Inc., the developer of the first rechargeable implantable Sacral Neuromodulation (SNM) System for the treatment of urinary and fecal dysfunction, announced today that its first patients ...
Irvine, California (ots/PRNewswire) - A Record Number of Operators on the Conference Agenda Light Reading will host its seventh Ethernet Europe [http://www.etherneteurope.com ] in Munich, Germany on April 17 and 18 at the Hilton Munich Park Hotel. This year's event is collocated with the Metro Ethernet Forum's Quarterly Meeting, making the conference one of the most compelling and productive events for the European ...
Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, an innovative molecular diagnostics company, today announced that its supervisory board of directors has appointed David Macdonald as chief executive officer. This follows the resignation of the company's co-founder and chief executive officer, Dr. Bernhard Sixt. Dr. Sixt will remain with the company in an advisory capacity. Agendia also announced the addition ...
BRUSSELS, IRVINE, California, and AMSTERDAM, October 18, 2011 (ots/PRNewswire) -- The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemotherapy Trial) study. More than ...
Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, an innovative molecular cancer diagnostics company, today announced that the company successfully completed a recent, routine inspection of its Irvine, California-based laboratories by the US Food and Drug Administration (FDA). Agendia received FDA 510(k) clearance for its MammaPrint(R) breast cancer recurrence test in early 2007. It remains the first and only ...
Irvine, California and Amsterdam (ots/PRNewswire) - - Peer-Reviewed Article Notes That Multi-Gene Subtyping Profile Provides Deeper Insight Into Breast Cancer Agendia, an innovative molecular cancer diagnostics company, today announced that a published report highlighting the development and validation of its 80-gene BluePrint breast cancer profile was published online ...